28.60

2.70% -0.81

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Financials Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is traded at $28.60, with a volume of 130.09K. It is down -2.70% in the last 24 hours and down -31.53% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Previous Close:

$29.41

Open:

$29.25

24h Volume:

130.09K

Relative Volume:

0.13

Market Cap:

$2.98B

Revenue:

Net Income/Loss:

$-804.34M

P/E Ratio:

-3.0393

EPS:

-9.41

Net Cash Flow:

$-531.06M

1W Performance:

-5.87%

1M Performance:

-31.53%

6M Performance:

-24.86%

1Y Performance:

-52.11%

1-Day Range:

$28.48

$29.73

1-Week Range:

$26.96

$31.08

52-Week Range:

$26.80

$60.46

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

203-404-0410

Address

215 CHURCH STREET, NEW HAVEN, CT

Employee

256

Twitter

@biohavenpharma

Next Earnings Date

2022-11-07T13:30:00.000Z

Latest SEC Filings

BHVN's Discussions on Twitter

Compare BHVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHVN Biohaven Ltd	28.55	2.98B	0	-804.34M	-531.06M	-9.41
VRTX Vertex Pharmaceuticals Inc	501.49	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	682.33	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.00	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.63	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Sep-16-24	Initiated	Jefferies	Buy
Sep-04-24	Initiated	Bernstein	Outperform
Jul-24-24	Initiated	Morgan Stanley	Overweight
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

Mar 12, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Investors to Learn More About the Investigation - Markets Insider

Mar 12, 2025

Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Mar 12, 2025

Mar 11, 2025

Biohaven Ltd. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biohaven Ltd. (BHVN) - ACCESS Newswire

Mar 11, 2025